The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
HOME > COMMENTARY
COMMENTARY
- COMMENTARY Major GE Houses Working to Increase Business with Wholesalers
November 13, 2006
- COMMENTARY New Promotion Code to Go into Effect Next January
October 30, 2006
- 70% of People 40 Years or Older Have Pain in Joints, Lower Back: Survey by Stryker
October 23, 2006
- Surveys by JMA, FTC Provide Evidence for Discussions on Generics
October 16, 2006
- COMMENTARY/Original and Generic Makers Should Cooperate for Stable Supply
September 11, 2006
- COMMENTARY Government Increases Efforts to Promote Clinical Research
September 4, 2006
- TOPICS 2 articles
August 28, 2006
- COMMENTARY/Government Increases Efforts to Promote Clinical Research
August 28, 2006
- Blockbuster Sales of International Majors in 2005: Rankings of Companies and Therapeutic Areas Keiji Nakamura, Ph.D. Pharma Forum Institute, Kamakura, Japan http://www.pharma-fi.com/index.html
August 21, 2006
- COMMENTARY 3 articles
August 7, 2006
- 5 Major New Drugs Affected by Listing of 1st Generics
July 31, 2006
- COMMENTARY:New Clinical Trial Stimulation Plan to Go in Tandem with New Industry Vision
July 17, 2006
- COMMENTARY Social Security Spending to Be Cut by \1.6 Tril.↓
July 10, 2006
- COMMENTARY Amended PAL to Remake Retail Industry
July 10, 2006
- Generic Drug Market Sees New Era of Competition 5 articles
July 3, 2006
- Drug Industry Reorganization in the Future ―No More Argument, Unexpected Leaders?―
June 19, 2006
- COMMENTARY 3 articles
June 19, 2006
- Predicting the Future Market for Smoking Cessation Aids: Will OTC Products Continue to Outsell Ethical Products?
June 5, 2006
- Major Domestic Companies Invest More Than Ever in R&D
May 29, 2006
- Incident in PI Trial in UK 5 articles
May 8, 2006
ページ
The pharmaceutical industry is ever-changing. Recruiters must evolve accordingly and prepare well in advance for future talent needs.This means predicting the changes and trends that will impact the market, industry, and your organization, and how this will affect talent requirements.…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…